Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.68 |
| ▸ | ACE | P12821 | 8/20 | 0.64 |
| ▸ | MME | P08473 | 1/20 | 0.64 |
| ▸ | TACR2 | P21452 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 3/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650545 | 0.97 | CASP3 (0.64) | CASP3ACEMMECASP1 | |
| SCHEMBL14641301 | 0.97 | CASP3 (0.64) | CASP3ACEMMECASP1 | |
| SCHEMBL14603133 | 0.97 | CASP3 (0.64) | CASP3ACEMMECASP1 | |
| SCHEMBL6394661 | 0.92 | CASP3 (0.58) | CASP3ACEMMECASP1 | |
| SCHEMBL6599837 | 0.91 | CASP3 (0.66) | CASP3ACEMMETACR2DPP4 | |
| SCHEMBL14603132 | 0.87 | CASP3 (0.61) | CASP3ACEMMECASP1 | |
| SCHEMBL14641489 | 0.87 | CASP3 (0.61) | CASP3ACEMMECASP1 | |
| SCHEMBL14603128 | 0.87 | CASP3 (0.61) | CASP3ACEMMECASP1 | |
| SCHEMBL6199732 | 0.86 | CASP3 (0.60) | CASP3TACR2CASP1 | |
| SCHEMBL8189734 | 0.84 | CASP3 (0.52) | CASP3ACECASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1156803-A4 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20020103335-A1 | PEPTIDE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2002-08-01 | — | — | US | disclosed |
| EP-1156803-A1 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6297233-B1 | Lactam inhibitors of FXa and method | BRISTOL-MYERS SQUIBB COMPANY | 2001-10-02 | — | — | US | disclosed |
| US-6207644-B1 | FOR USE IN TREATING MHC CLASS II DEPENDENT T-CELL MEDIATED AUTOIMMUNE OR INFLAMMATORY DISEASES, SUCH AS RHEUMATOID ARTHRITIS | ZENECA LIMITED (GB) | 2001-03-27 | — | — | US | disclosed |
| WO-2000047207-A1 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-17 | — | — | WO | disclosed |
| EP-0932618-A1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | AstraZeneca AB (SE) | 1999-08-04 | — | — | EP | disclosed |
| EP-0914333-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998017680-A1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | ZENECA LIMITED (GB) | 1998-04-30 | — | — | WO | disclosed |
| WO-1997046578-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103335-A1 | PEPTIDE DERIVATIVES | HLA-DRB1, MICA, TAP1 | CASP3 1606/4885ACE 708/4885MME 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.